title: [A case of lung metastasis from esophageal cancer resistant to fluorouracil and cisplatin combination therapy but responsive to radiation therapy].
abstract: At present, fluorouracil and cisplatin combination therapy is the standard chemotherapy against esophageal cancer, but the choice of second-line chemotherapy is controversial. Furthermore, the effect of radiation therapy against lung metastasis from esophageal cancer is unclear. We report a case of lung metastasis from esophageal cancer resistant to fluorouracil and cisplatin combination therapy but responsive to radiation therapy. The patient was a 55-year-old woman who had undergone an operation for esophageal cancer at another hospital. A single right lung metastasis appeared 1 year after the operation. Combined fluorouracil and cisplatin therapy was administrated for 5 courses, but the lung metastasis increased in size. Afterwards, she was admitted to our hospital. We treated her with 14 courses of S-1 and docetaxel combination therapy administered over 13 months. The lung metastasis was decreased for a period. Furthermore, radiofrequency ablation under computed tomography was performed against the lung metastasis re-growth at another hospital. Although the lung metastasis increased in size, no further metastases were detected during the clinical course. The patient was treated with radiotherapy for the lung metastasis re-growth. The tumor had almost disappeared by 10 months after the completion of radiotherapy. Currently, she is receiving palliative care as an outpatient and the lung metastasis has not been evident for 2 years since the completion of radiotherapy.
authors.affiliation: Dept. of Surgery, Tokyo Metropolitan Toshima Hospital, Japan.
authors.forename: Katsunori
authors.initials: K
authors.lastname: Ami
authors.forename: Ryouta
authors.initials: R
authors.lastname: Seki
authors.forename: Jun
authors.initials: J
authors.lastname: Takasaki
authors.forename: Hidetoshi
authors.initials: H
authors.lastname: Amagasa
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Kamikozuru
authors.forename: Hideaki
authors.initials: H
authors.lastname: Ganno
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Kurokawa
authors.forename: Akira
authors.initials: A
authors.lastname: Fukuda
authors.forename: Takeshi
authors.initials: T
authors.lastname: Nagahama
authors.forename: Masayuki
authors.initials: M
authors.lastname: Ando
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Yamada
authors.forename: Fumi
authors.initials: F
authors.lastname: Kodaka
authors.forename: Kuniyoshi
authors.initials: K
authors.lastname: Arai
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D059248:Chemoradiotherapy; D002945:Cisplatin / Q000008:administration & dosage; D004938:Esophageal Neoplasms / Q000473:pathology / Q000628:therapy*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary / Q000628:therapy*; D008875:Middle Aged; D011788:Quality of Life
chemical_list: D002945:Cisplatin; D005472:Fluorouracil